UNSPSC 51101638: Bialamicol

This classification denotes an antiprotozoal agent with the molecular formula C28H40N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TA5NM093QJ, chemically known as 5,5-diallyl-alpha,alpha-bis(diethylamino)-n,n-bitolyl-4,4-diol but generally known as bialamicol, which bears US NIH Compound Identifier 10304. Bialamicol most often comes in base and hydrochloride forms. European Medicines Agency schedules Bialamicol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05812MIG.

UNSPSC 51101638 Bialamicol, a Commodity code, shows little relevant recent activity—the recent opportunities tagged under this code involve naloxone and drug deactivation systems, generic pharmaceuticals and OTC products, and medical first-aid supplies, none of which align with bialamicol's actual scope as a chemical or pharmaceutical ingredient. State and local governments do procure medical supplies, pharmaceuticals, and naloxone through public health and emergency management channels, but the tagging of these opportunities under bialamicol does not reflect the code's intended commodity. The mismatch suggests either classification inconsistency in the source data or limited use of this specific code in state and local procurement taxonomies.

Geographic activity appears concentrated in Florida and the upper Midwest, with recent opportunities in Seminole County, Florida; Texas Health and Human Services Commission; the City of Tampa, Florida; and Minnesota through the multistate cooperative purchasing vehicle MMCAP. Issuing bodies include county health departments, state health commissions, city fire departments, and cooperative purchasing alliances serving multiple jurisdictions. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (response deadline July 26, 2023), the City of Tampa's invitation to bid for medical and first aid supplies for the Fire Department Rescue Division (response deadline March 13, 2026, estimated contract value $700,000), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (response deadline March 26, 2026). The actual procurement activity under codes near or overlapping this commodity involves consumable medical products, emergency response supplies, and pharmaceutical distribution rather than bialamicol itself.